The estimated Net Worth of Jacob Chacko is at least $11 Milione dollars as of 6 March 2024. Dr Chacko owns over 40,000 units of Oric Pharmaceuticals stock worth over $7,212,586 and over the last 9 years he sold ORIC stock worth over $2,967,080. In addition, he makes $790,955 as Pres e CEO & Director at Oric Pharmaceuticals.
Dr has made over 20 trades of the Oric Pharmaceuticals stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 40,000 units of ORIC stock worth $648,400 on 6 March 2024.
The largest trade he's ever made was buying 450,000 units of Oric Pharmaceuticals stock on 11 May 2022 worth over $1,287,000. On average, Dr trades about 29,172 units every 81 days since 2016. As of 6 March 2024 he still owns at least 728,544 units of Oric Pharmaceuticals stock.
You can see the complete history of Dr Chacko stock trades at the bottom of the page.
Dr. Jacob M. Chacko M.B.A., M.D. is the Pres, CEO & Director at Oric Pharmaceuticals.
As the Pres e CEO & Director of Oric Pharmaceuticals, the total compensation of Dr D at Oric Pharmaceuticals is $790,955. There are no executives at Oric Pharmaceuticals getting paid more.
Dr D is 42, he's been the Pres e CEO & Director of Oric Pharmaceuticals since . There are 10 older and no younger executives at Oric Pharmaceuticals. The oldest executive at Oric Pharmaceuticals, Inc. is Dr. Richard A. Heyman Ph.D., 64, who is the Co-Founder, Independent Chairman & Member of Scientific Advisory Board.
Jacob's mailing address filed with the SEC is C/O 4D MOLECULAR THERAPEUTICS, INC., 5858 HORTON STREET #455, EMERYVILLE, CA, 94608.
Over the last 5 years, insiders at Oric Pharmaceuticals have traded over $33,873,532 worth of Oric Pharmaceuticals stock and bought 1,422,500 units worth $12,330,600 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon e Peter Svennilson. On average, Oric Pharmaceuticals executives and independent directors trade stock every 29 days with the average trade being worth of $996,237. The most recent stock trade was executed by Lori Anne Kunkel on 3 June 2024, trading 20,500 units of ORIC stock currently worth $76,875.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Oric Pharmaceuticals executives and other stock owners filed with the SEC include: